Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | GOT1 | P17174 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25337613 | 0.82 | BACE1 (0.44) | DRD2DRD4DRD3GOT1GAA | |
| SCHEMBL26119201 | 0.81 | MAPK14 (0.40) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL17634311 | 0.78 | HTR6 (0.41) | DRD2DRD4DRD3MAPTHTR6 | |
| SCHEMBL19284723 | 0.77 | HTR6 (0.65) | DRD2DRD4DRD3GOT1GAA | |
| SCHEMBL20142178 | 0.75 | KEAP1 (0.36) | DRD2DRD4DRD3GOT1GAA | |
| SCHEMBL20141537 | 0.74 | KEAP1 (0.47) | GOT1GAAMAPTRECQLALDH1A1 | |
| SCHEMBL5704915 | 0.72 | DRD2 (0.50) | DRD2DRD4DRD3GOT1GAA | |
| SCHEMBL2228008 | 0.71 | GOT1 (0.70) | DRD2DRD4DRD3GOT1GAA | |
| SCHEMBL16026477 | 0.69 | AKT2 (0.59) | GOT1KITAKT1 | |
| SCHEMBL3723654 | 0.69 | KIT (0.46) | KITAKT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | DRD2 2552/4885DRD4 2521/4885DRD3 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.